-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2021, under the continuous changes in the pharmaceutical environment, the senior management of pharmaceutical companies has continued to change.
Among them, the chairmanship alone involves 21 pharmaceutical companies, including Hengrui Pharmaceutical, Guangyuyuan, Northeast Pharmaceutical, etc.
, and the Chinese medicine giant Pien Tze Huang is even more involved.
Two chairman of the board were replaced during the year
.
In April this year, Pien Tze Huang announced that the former chairman Liu Jianshun applied for early retirement due to personal physical reasons, and Pan Jie took over
.
According to the data, in May 1999, senior economist Pan Jie joined Pien Tze Huang as the deputy factory director of the pharmaceutical factory, and then worked competently until he left in December 2014.
He has served as director, deputy general manager, general manager and other positions of the company
.
After 8 years, Pan Jie returned to Pien Tze Huang as the chairman of the board
.
However, Pan Jie has served as chairman of the board for only eight months.
On December 9th, Pien Tze Huang announced again that due to work adjustments, Mr.
Pan Jie resigned from the board of directors, chairman of the board, and members of special committees under the board of directors
.
After resignation, Pan Jie no longer holds any position in Pien Tze Huang
.
At the same time, the board of directors agreed to appoint Mr.
Lin Weiqi as the chairman of the company for the same term as the sixth board of directors
.
Some analysts pointed out that Pan Jie was ordered in danger in April.
After the previous chairman resigned due to physical problems, he took over as the chairman of Pien Tze Huang
.
It is worth mentioning that, despite the rush to work, Pien Tze Huang's performance has increased significantly during the eight months of Pan Jie's tenure as chairman
.
According to data, Pien Tze Huang is a major domestic liver disease Chinese medicine company.
The source of its prescriptions can be traced back to the Jiajing Year of the Ming Dynasty in 1555.
The main raw materials are natural musk and bezoar
.
The actual controller Zhangzhou State-owned Assets Supervision and Administration Commission, through its subsidiary Zhangzhou Jiulongjiang Group, holds 57.
92% of the shares
.
Another important shareholder is Wang Fuji, who holds 4.
48% of the shares.
He bought about 200 million yuan in stocks from 2009 to 2010, and held a stock market value of about 12 billion yuan in the first quarter of 2021
.
The third quarter report of 2021 shows that in the first three quarters of 2021, Pien Tze Huang achieved revenue of 6.
112 billion yuan, a year-on-year increase of 20.
55%; net profit was 2.
061 billion yuan, a year-on-year increase of 52.
34%
.
Among them, the net profit of the second quarter and the third quarter reached 552 million yuan and 919 million yuan, respectively, 36% and 96% year-on-year
.
In the third quarter of this year, Pien Tze Huang set a new record for its single-quarter net profit since its listing, with a single-quarter net profit exceeding half of the full-year 2020
.
It is reported that Pien Tze Huang’s profit increase is due to the active expansion of online sales channels and cost control, coupled with the continuous expansion of experience halls, regional distribution, retail pharmacies, online flagship stores and other methods, the rapid increase in performance has been achieved
.
In addition, when Pan Jie took office, the total market value of Pien Tze Huang was about 200 billion yuan, and then soared.
As of December 9, the total market value of Pien Tze Huang was 281.
1 billion yuan, an increase of about 40%
.
In this regard, Pien Tze Huang also affirmed Pan Jie's achievements and stated in the announcement that Pan Jie has promoted the company's continued growth
.
It is understood that Lin Weiqi, who took over as chairman this time, was born in 1966, only one year younger than Pan Jie
.
According to the announcement, Lin Weiqi had worked in the Education Bureau, Foreign Economic and Trade Commission, and Foreign Investment Section of Dongshan County, Zhangzhou City
.
From 2001 to 2014, he served successively as assistant to general manager and deputy general manager of Hong Kong Zhanglong Industrial Co.
, Ltd.
, and member and deputy director of the Party Committee of Zhangzhou State-owned Assets Supervision and Administration Commission from 2014 to 2021
.
On the day when Lin Weiqi became chairman, Pien Tze Huang's stock price was undervalued by 300.
57 yuan per share, with a total market value of about 200 billion yuan
.
As of the close of the market on December 9, Pien Tze Huang's stock price was reported at 465.
98 yuan per share, with a total market value of 281.
1 billion yuan
.
Will the future successor Lin Weiqi take Pien Tze Huang to create a new myth? It deserves the industry's continued attention
.
Among them, the chairmanship alone involves 21 pharmaceutical companies, including Hengrui Pharmaceutical, Guangyuyuan, Northeast Pharmaceutical, etc.
, and the Chinese medicine giant Pien Tze Huang is even more involved.
Two chairman of the board were replaced during the year
.
In April this year, Pien Tze Huang announced that the former chairman Liu Jianshun applied for early retirement due to personal physical reasons, and Pan Jie took over
.
According to the data, in May 1999, senior economist Pan Jie joined Pien Tze Huang as the deputy factory director of the pharmaceutical factory, and then worked competently until he left in December 2014.
He has served as director, deputy general manager, general manager and other positions of the company
.
After 8 years, Pan Jie returned to Pien Tze Huang as the chairman of the board
.
However, Pan Jie has served as chairman of the board for only eight months.
On December 9th, Pien Tze Huang announced again that due to work adjustments, Mr.
Pan Jie resigned from the board of directors, chairman of the board, and members of special committees under the board of directors
.
After resignation, Pan Jie no longer holds any position in Pien Tze Huang
.
At the same time, the board of directors agreed to appoint Mr.
Lin Weiqi as the chairman of the company for the same term as the sixth board of directors
.
Some analysts pointed out that Pan Jie was ordered in danger in April.
After the previous chairman resigned due to physical problems, he took over as the chairman of Pien Tze Huang
.
It is worth mentioning that, despite the rush to work, Pien Tze Huang's performance has increased significantly during the eight months of Pan Jie's tenure as chairman
.
According to data, Pien Tze Huang is a major domestic liver disease Chinese medicine company.
The source of its prescriptions can be traced back to the Jiajing Year of the Ming Dynasty in 1555.
The main raw materials are natural musk and bezoar
.
The actual controller Zhangzhou State-owned Assets Supervision and Administration Commission, through its subsidiary Zhangzhou Jiulongjiang Group, holds 57.
92% of the shares
.
Another important shareholder is Wang Fuji, who holds 4.
48% of the shares.
He bought about 200 million yuan in stocks from 2009 to 2010, and held a stock market value of about 12 billion yuan in the first quarter of 2021
.
The third quarter report of 2021 shows that in the first three quarters of 2021, Pien Tze Huang achieved revenue of 6.
112 billion yuan, a year-on-year increase of 20.
55%; net profit was 2.
061 billion yuan, a year-on-year increase of 52.
34%
.
Among them, the net profit of the second quarter and the third quarter reached 552 million yuan and 919 million yuan, respectively, 36% and 96% year-on-year
.
In the third quarter of this year, Pien Tze Huang set a new record for its single-quarter net profit since its listing, with a single-quarter net profit exceeding half of the full-year 2020
.
It is reported that Pien Tze Huang’s profit increase is due to the active expansion of online sales channels and cost control, coupled with the continuous expansion of experience halls, regional distribution, retail pharmacies, online flagship stores and other methods, the rapid increase in performance has been achieved
.
In addition, when Pan Jie took office, the total market value of Pien Tze Huang was about 200 billion yuan, and then soared.
As of December 9, the total market value of Pien Tze Huang was 281.
1 billion yuan, an increase of about 40%
.
In this regard, Pien Tze Huang also affirmed Pan Jie's achievements and stated in the announcement that Pan Jie has promoted the company's continued growth
.
It is understood that Lin Weiqi, who took over as chairman this time, was born in 1966, only one year younger than Pan Jie
.
According to the announcement, Lin Weiqi had worked in the Education Bureau, Foreign Economic and Trade Commission, and Foreign Investment Section of Dongshan County, Zhangzhou City
.
From 2001 to 2014, he served successively as assistant to general manager and deputy general manager of Hong Kong Zhanglong Industrial Co.
, Ltd.
, and member and deputy director of the Party Committee of Zhangzhou State-owned Assets Supervision and Administration Commission from 2014 to 2021
.
On the day when Lin Weiqi became chairman, Pien Tze Huang's stock price was undervalued by 300.
57 yuan per share, with a total market value of about 200 billion yuan
.
As of the close of the market on December 9, Pien Tze Huang's stock price was reported at 465.
98 yuan per share, with a total market value of 281.
1 billion yuan
.
Will the future successor Lin Weiqi take Pien Tze Huang to create a new myth? It deserves the industry's continued attention
.
